Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DWTX NASDAQ:LSB NASDAQ:PCSA NASDAQ:TLPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDWTXDogwood Therapeutics$4.50-4.3%$4.99$1.62▼$29.28$8.98M1.81.45 million shs47,002 shsLSBLakeShore Biopharma$1.12+5.7%$1.05$0.87▼$8.60$9.87M0.5888,071 shs90,990 shsPCSAHeatwurx$0.22+5.6%$0.25$0.15▼$3.10$2.44M1.35.32 million shs2.09 million shsTLPHTalphera$0.43-1.7%$0.49$0.38▼$1.19$8.97M-0.11136,163 shs279,827 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDWTXDogwood Therapeutics-4.26%-8.54%-6.05%+5.39%+449,999,900.00%LSBLakeShore Biopharma+5.66%-5.88%+12.00%-15.09%-76.62%PCSAHeatwurx+5.60%-10.67%-3.64%-1.41%-87.61%TLPHTalphera-1.69%-14.68%-10.60%-10.60%-52.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDWTXDogwood Therapeutics1.8698 of 5 stars3.50.00.00.02.70.00.6LSBLakeShore Biopharma0.7253 of 5 stars0.03.00.00.02.70.80.6PCSAHeatwurx3.1437 of 5 stars3.52.00.00.03.81.71.3TLPHTalphera2.366 of 5 stars3.82.00.00.03.30.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDWTXDogwood Therapeutics 3.00Buy$10.00122.22% UpsideLSBLakeShore Biopharma 0.00N/AN/AN/APCSAHeatwurx 3.00Buy$2.00822.08% UpsideTLPHTalphera 3.50Strong Buy$5.001,062.79% UpsideCurrent Analyst Ratings BreakdownLatest PCSA, LSB, TLPH, and DWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025PCSAHeatwurxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $2.004/23/2025DWTXDogwood TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$10.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDWTXDogwood TherapeuticsN/AN/AN/AN/A($7.56) per shareN/ALSBLakeShore Biopharma$672.27M0.02N/AN/A$8.86 per share0.13PCSAHeatwurxN/AN/AN/AN/A$0.46 per shareN/ATLPHTalphera$650K13.56N/AN/A$0.47 per share0.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDWTXDogwood Therapeutics-$12.35M-$18.04N/AN/AN/AN/AN/A-34.74%8/6/2025 (Estimated)LSBLakeShore Biopharma-$61.09MN/A0.00∞N/AN/AN/AN/A8/21/2025 (Estimated)PCSAHeatwurx-$11.85M-$3.08N/AN/AN/AN/A-319.56%-232.40%8/12/2025 (Estimated)TLPHTalphera-$13M-$0.45N/AN/AN/AN/A-130.28%-59.25%8/13/2025 (Estimated)Latest PCSA, LSB, TLPH, and DWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025DWTXDogwood Therapeutics-$1.26N/AN/AN/AN/AN/A8/13/2025Q2 2025TLPHTalphera-$0.1150N/AN/AN/AN/AN/A8/12/2025Q2 2025PCSAHeatwurx-$0.23N/AN/AN/AN/AN/A5/8/2025Q1 2025DWTXDogwood Therapeutics-$0.77-$4.21-$3.44-$8.45N/AN/A5/8/2025Q1 2025PCSAHeatwurx-$0.77-$0.30+$0.47-$0.30N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDWTXDogwood TherapeuticsN/AN/AN/AN/AN/ALSBLakeShore BiopharmaN/AN/AN/AN/AN/APCSAHeatwurxN/AN/AN/AN/AN/ATLPHTalpheraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDWTXDogwood TherapeuticsN/A7.437.43LSBLakeShore BiopharmaN/AN/AN/APCSAHeatwurxN/A2.932.93TLPHTalpheraN/A3.113.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDWTXDogwood Therapeutics9.05%LSBLakeShore Biopharma52.64%PCSAHeatwurx91.93%TLPHTalphera37.67%Insider OwnershipCompanyInsider OwnershipDWTXDogwood Therapeutics3.90%LSBLakeShore BiopharmaN/APCSAHeatwurx9.60%TLPHTalphera3.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDWTXDogwood Therapeutics51.91 million1.84 millionN/ALSBLakeShore Biopharma7739.31 millionN/AN/APCSAHeatwurx2011.88 million10.74 millionNot OptionableTLPHTalphera1920.50 million19.85 millionOptionablePCSA, LSB, TLPH, and DWTX HeadlinesRecent News About These Companiestalphera receives extension to meet nasdaq listing requirementsJune 7, 2025 | investing.comTalphera Granted Extension for Nasdaq ComplianceJune 5, 2025 | tipranks.comTalphera, Inc.: Talphera Announces First Quarter 2025 Financial Results and Provides Corporate UpdateMay 17, 2025 | finanznachrichten.deEarnings call transcript: Talphera Inc. outlines strategic shifts in Q1 2025May 16, 2025 | uk.investing.comTalphera, Inc. (NASDAQ:TLPH) Q1 2025 Earnings Call TranscriptMay 16, 2025 | msn.comTalphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financingMay 15, 2025 | msn.comTalphera, Inc. (TLPH) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comTalphera Announces First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | prnewswire.comTalphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025May 7, 2025 | prnewswire.comAll You Need to Know About Talphera (TLPH) Rating Upgrade to Strong BuyMay 7, 2025 | msn.comTalphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock?April 5, 2025 | msn.comTalphera reports Q4 EPS (7c) vs. (25c) last yearApril 1, 2025 | markets.businessinsider.comTalphera, Inc. (NASDAQ:TLPH) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comTalphera announces agreement with FDA to reduce NEPHRO CRRT study sizeApril 1, 2025 | markets.businessinsider.comTalphera Reports 2024 Financial Results and Study UpdateMarch 31, 2025 | tipranks.comTalphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of NiyadMarch 31, 2025 | msn.comTalphera, Inc. (TLPH) Q4 2024 Earnings Call TranscriptMarch 31, 2025 | seekingalpha.comTalphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 31, 2025 | prnewswire.comTalphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 MillionMarch 31, 2025 | prnewswire.com7TLPH : Earnings Outlook For TalpheraMarch 28, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePCSA, LSB, TLPH, and DWTX Company DescriptionsDogwood Therapeutics NASDAQ:DWTX$4.50 -0.20 (-4.26%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$4.64 +0.14 (+3.00%) As of 08:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.LakeShore Biopharma NASDAQ:LSB$1.12 +0.06 (+5.66%) Closing price 07/16/2025 03:53 PM EasternExtended Trading$1.14 +0.02 (+1.79%) As of 09:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.Heatwurx NASDAQ:PCSA$0.22 +0.01 (+5.60%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$0.22 +0.00 (+0.51%) As of 09:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.Talphera NASDAQ:TLPH$0.43 -0.01 (-1.69%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$0.40 -0.03 (-6.28%) As of 09:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Citigroup Earnings Could Signal What’s Next for Markets This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
